ReviewOrphanet journal of rare diseases2019
Update on the management of colchicine resistant Familial Mediterranean Fever (FMF).
Review in Orphanet journal of rare diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 66 citations in OpenAlex.
- JAK Inhibitors in Colchicine Resistant FMF Patients: A Case-Based Review.Mediterranean journal of rheumatology · 2026Article
- Factors Affecting the Use of Colchicine in FMF Patients and Alternative Treatments in FMF Management: Limits of Colchicine and Solutions.The Yale journal of biology and medicine · 2026Article
- Navigating Bariatric Surgery in Familial Mediterranean Fever.Obesity surgery · 2025Article
- The Role ofInternational journal of molecular sciences · 2025Article
- Arterial Stiffness and Subclinical Inflammation in Children with Familial Mediterranean Fever: A Comprehensive Analysis.Children (Basel, Switzerland) · 2025Article
- Familial Mediterranean Fever (FMF): Emerging Concepts in Diagnosis, Pain Management, and Novel Treatment Options: A Narrative Review.Current pain and headache reports · 2025Review
- Impact of celiac disease on patients with familial Mediterranean fever: a nationwide study based on the Türkiye database.Frontiers in immunology · 2025Article
- Familial Mediterranean Fever as a Cause of Recurrent Pleurisy in a Child With Crohn's Disease: A Case Report.Case reports in pulmonology · 2025Article
- Swollen Feet: Considering the Paradoxical Roles of Interleukins in Nephrotic Syndrome.Biomedicines · 2024Review
- Updates on the role of epigenetics in familial mediterranean fever (FMF).Orphanet journal of rare diseases · 2024Review
- A narrative review on the role of cytokines in the pathogenesis and treatment of familial Mediterranean fever: an emphasis on pediatric cases.Frontiers in pediatrics · 2024Review
- An Update on Familial Mediterranean Fever.International journal of molecular sciences · 2023Review
- Evaluation of periodontal status and cytokine response in children with familial Mediterranean fever or systemic juvenile idiopathic arthritis.Clinical oral investigations · 2023Article
- Effect of interleukin-1 antagonist on growth of children with colchicine resistant or intolerant FMF.Pediatric rheumatology online journal · 2023Article
- Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy.Journal of market access & health policy · 2023Article
- The Clinical Outcomes of COVID-19 in Patients with Behçet's Disease: A Series of 7 Cases and Brief Review of the Literature.The Eurasian journal of medicine · 2022Article
- Does Pyroptosis Play a Role in Inflammasome-Related Disorders?International journal of molecular sciences · 2022Review
- IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting.Nature reviews. Rheumatology · 2022Review
- Chemical Modulation of Gasdermin-Mediated Pyroptosis and Therapeutic Potential.Journal of molecular biology · 2022Review
- Cardiac Tamponade: A Rare Manifestation of Familial Mediterranean Fever.Case reports in rheumatology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFamilial Mediterranean Fever (FMF), an autoinflammatory disease, is characterized by self-limited inflammatory attacks of fever and polyserositis along with high acute phase response. Although colchicine remains the mainstay in treatment, intolerance and resistance in a certain portion of patients have been posing a problem for physicians. MAIN BODY: Like many autoimmune and autoinflammatory diseases, many colchicine-resistant or intolerant FMF cases have been successfully treated with biologics. In addition, many studies have tested the efficacy of biologics in treating FMF manifestations.
conclusionSince carriers of FMF show significantly elevated levels of serum TNF alpha, IL-1, and IL-6, FMF patients who failed colchicine were successfully treated with anti IL-1, anti IL-6, or TNF inhibitors drugs. It is best to use colchicine in combination with biologics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.